Patients with NYHA FC II-III heart failure will be randomized in a cross-over fashion to 8
weeks of bumetanide versus furosemide therapy (equipotent dose), to test whether bumetanide
therapy has a superior effect on insulin resistance compared to furosemide. Patients will be
subject to a frequently sampled intravenous glucose tolerance test (FSIGT) with minimal model
(MINMOD) analysis to assess insulin resistance and to a 6-minute walk test (6MWT) to assess
functional capacity; patient recruitment and retention success, as well as medication
adherence, will also be assessed.
Patients with NYHA FC II-III heart failure will be randomized in a cross-over fashion to 8
weeks of bumetanide versus furosemide therapy (equipotent dose), to test whether bumetanide
therapy has a superior effect on insulin resistance compared to furosemide. Patients will be
subject to a frequently sampled intravenous glucose tolerance test (FSIGT) with minimal model
(MINMOD) analysis to assess insulin resistance and to a 6-minute walk test (6MWT) to assess
functional capacity; patient recruitment and retention success, as well as medication
adherence, will also be assessed.
The main goal of the study is to obtain pharmacokinetic and safety data of bumetanide in
newborns with refractory seizures. The overall hypothesis is that bumetanide, added to
conventional antiepileptic (antiseizure) medications, will be a safe and well tolerated
medication, compared with conventional antiepileptic drugs alone.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
